{"mainPropery":{"diseaseId":2835,"diseaseName":"Primary hyperoxaluria type 1","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/2835/primary-hyperoxaluria-type-1","synonyms":["HP1","Oxalosis 1","Glycolic aciduria","Alanine-glyoxylate aminotransferase deficiency","Peroxisomal alanine glyoxylate aminotransferase deficiency","Hepatic AGT deficiency","Serine pyruvate aminotransferase deficiency"],"synonyms-with-source":[{"name":"HP1"},{"name":"Oxalosis 1"},{"name":"Glycolic aciduria"},{"name":"Alanine-glyoxylate aminotransferase deficiency"},{"name":"Peroxisomal alanine glyoxylate aminotransferase deficiency"},{"name":"Hepatic AGT deficiency"},{"name":"Serine pyruvate aminotransferase deficiency"}],"identifiers":[{"identifierType":"OMIM","identifierId":"259900"},{"identifierType":"ORPHANET","identifierId":"93598"},{"identifierType":"UMLS","identifierId":"C0268164"}]},"diseaseCategories":[{"diseaseTypeId":5,"diseaseTypeName":"Congenital and Genetic Diseases","source":"Orphanet"},{"diseaseTypeId":26,"diseaseTypeName":"Kidney and Urinary Diseases","source":"Orphanet"},{"diseaseTypeId":14,"diseaseTypeName":"Metabolic disorders"},{"diseaseTypeId":33,"diseaseTypeName":"RDCRN"}],"organizations":[{"resourceID":97,"resourceName":"National Kidney Foundation","abbreviation":"","address1":"30 East 33rd Street","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10016","country":"United States","phone":"212-889-2210","tty":"","tollFree":"800-622-9010","fax":"212-689-9261","email":"info@kidney.org","url":"https://www.kidney.org/","freeText":""},{"resourceID":114,"resourceName":"American Association of Kidney Patients","abbreviation":"","address1":"3505 E. Frontage Rd., Suite 315","address2":"","address3":"","address4":"","address5":"","city":"Tampa","state":"FL","zip":"33607-1796","country":"United States","phone":"813-636-8100","tty":"","tollFree":"800-749-2257","fax":"813-636-8122","email":"info@aakp.org","url":"http://www.aakp.org","freeText":""},{"resourceID":138,"resourceName":"Metabolic Support UK","abbreviation":"","address1":"5 Hilliards Court","address2":"Sandpiper Way","address3":"Chester Business Park","address4":"","address5":"","city":"Chester","state":"","zip":"CH4 9QP","country":"United Kingdom","phone":"0845 241 2173","tty":"","tollFree":"0800 652 3181 ","fax":"","email":"https://www.metabolicsupportuk.org/contact-us","url":"https://www.metabolicsupportuk.org","freeText":""},{"resourceID":505,"resourceName":"The Kidney Foundation of Canada","address1":"700-15 Gervais Drive","address2":"Toronto Ontario M3C 1Y8","address3":"","address4":"","address5":"","city":"","state":"","zip":"","country":"Canada","phone":"416-445-0373 ","tty":"","tollFree":"800-387-4474","fax":"416-445-7440 ","email":"kidney@kidney.on.ca","url":"http://www.kidney.on.ca"},{"resourceID":867,"resourceName":"Oxalosis and Hyperoxaluria Foundation (OHF)","abbreviation":"","address1":"579 Albany Post Road","address2":"","address3":"","address4":"","address5":"","city":"New Paltz","state":"NY","zip":"12561","country":"United States","phone":"212-777-0470","tty":"","tollFree":"1-800-OHF-8699","fax":"","email":"info@ohf.org","url":"http://ohf.org/","freeText":""},{"resourceID":2985,"resourceName":"National Kidney Federation","abbreviation":"NKF","address1":"The Point ","address2":"Shireoaks","address3":"Coach Road","address4":"Worksop","address5":"Notts S81 8BW","city":"","state":"","zip":"","country":"United Kingdom","phone":"0845 601 02 09","tty":"","tollFree":"","fax":"","email":"","url":"http://www.kidney.org.uk/","freeText":""}],"resource descriptions":[{"id":7,"resourceId":10,"resourceName":"Online Mendelian Inheritance in Man (OMIM)","descriptionText":"<a href='http://www.omim.org/259900' target='_blank'>Online Mendelian Inheritance in Man (OMIM)</a> is a catalog of human genes and genetic disorders. Each entry has a summary of related medical articles. It is meant for health care professionals and researchers. OMIM is maintained by Johns Hopkins University School of Medicine.&nbsp;<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=omim&cmd=Display&dopt=omim_pubmed_calculated&from_uid=259900' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Primary hyperoxaluria type 1. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Primary+hyperoxaluria+type+1%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Primary hyperoxaluria type 1. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition/primary-hyperoxaluria' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Primary hyperoxaluria type 1. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":878,"resourceId":1584,"resourceName":"RDCRN - Rare Kidney Stone Consortium","descriptionText":"The&nbsp;<a href='http://www.rarekidneystones.org/' target='_blank'>Rare Kidney Stone Consortium</a> is a team of doctors, nurses, research coordinators, and research labs throughout the U.S., working together to improve the lives of people with&nbsp;primary hyperoxaluria, cystinuria, dihydroxyadeninuria, and Dent's disease&nbsp;through research. The&nbsp;Rare Kidney Stone Consortium has a registry for patients who wish to be contacted about clinical research opportunities.","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"},{"id":1457,"resourceId":2104,"resourceName":"Genetic Services","descriptionText":"To find a medical professional who specializes in genetics, you can ask your doctor for a referral or you can search for one yourself. Online directories are provided by the <a href='http://www.acmg.net/ACMG/Genetic_Services_Directory_Search.aspx' target='_blank'>American College of Medical Genetics</a> and the&nbsp;<a href='https://www.findageneticcounselor.com/' target='_blank'>National Society of Genetic Counselors</a>. If you need additional help, <a href=\"https://rarediseases.info.nih.gov/about-gard/contact-gard\">contact a GARD Information Specialist</a>. You can also&nbsp;<a href='https://ghr.nlm.nih.gov/primer#consult' target='_blank'>learn more about genetic consultations</a>&nbsp;from Genetics Home Reference.","resourceClassificationName":"Find a Specialist","resourceClassificationSectionName":"Healthcare Resources"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C0268164/' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://rarediseases.org/rare-diseases/primary-hyperoxaluria/' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93598' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":1537,"resourceId":2168,"resourceName":"GeneReviews","descriptionText":"<a href='http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=ph1' target='_blank'>GeneReviews</a> provides current, expert-authored, peer-reviewed, full-text articles describing the application of genetic testing to the diagnosis, management, and genetic counseling of patients with specific inherited conditions.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:259900' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2184,"resourceId":867,"resourceName":"Oxalosis and Hyperoxaluria Foundation (OHF)","descriptionText":"The&nbsp;<a href='http://ohf.org/overview/' target='_blank'>Oxalosis and Hyperoxaluria Foundation (OHF)</a>, the leading organization dedicated to the awareness, understanding and treatment of primary hyperoxaluria, provides information about this condition.&nbsp;","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2722,"resourceId":4053,"resourceName":"Patient Registry","descriptionText":"A registry supports research by collecting of information about patients that share something in common, such as being diagnosed with Primary hyperoxaluria type 1. The type of data collected can vary from registry to registry and is based on the goals and purpose of that registry. Some registries collect contact information while others collect more detailed medical information. <a href=\"https://www.nih.gov/health-information/nih-clinical-research-trials-you/list-registries\" target=\"_blank\">Learn more about registries</a>.<br />\r\n<br />\r\nRegistries for&nbsp;Primary hyperoxaluria type 1:<br />\r\n<a href='https://www.mayo.edu/research/departments-divisions/department-internal-medicine/division-nephrology-hypertension/rare-kidney-stone-consortium-registry/rare-kidney-stone-consortium-registry' target='_blank'>International Registry for Hereditary Calcium Stone Diseases</a><br /><a href='https://ohf.org/patient-registry/' target='_blank'>The Primary Hyperoxaluria Registry</a><br />&nbsp;","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"}],"overviewQuestion":{"questionId":9490,"questionText":"What is primary hyperoxaluria type 1?","answerText":"<strong>Primary hyperoxaluria type 1</strong> (PH1) is a rare disorder that mainly affects the kidneys. It results from buildup of a substance called oxalate, which normally is filtered through the kidneys and excreted in the urine. In people with PH1, the accumulated oxalate is deposited in the kidneys and urinary tract. It combines with calcium, forming the main component of kidney and bladder stones (calcium oxalate).[12023][12024]<br />\r\n<br />\r\nSigns and symptoms of PH1 vary in severity and may begin any time from infancy to early adulthood. Symptoms may include recurrent <a href=\"https://medlineplus.gov/ency/article/000458.htm\" target=\"_blank\">kidney stones</a>; blood in the urine; and urinary tract infections. Left untreated, PH1 can result in <a href=\"https://medlineplus.gov/kidneyfailure.html\" target=\"_blank\">end-stage renal disease</a>, which is life-threatening.[12023][12024]<br />\r\n<br />\r\nPH1 is due to <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>  in a gene called <em><a href=\"https://ghr.nlm.nih.gov/gene/AGXT\" target=\"_blank\">AGXT</a></em>. Inheritance is <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>.[12023]<br />\r\n<br />\r\nEarly treatment is important for maintaining kidney function. Each person's treatment plan depends on his/her symptoms and the severity of the condition. Management may involve high fluid intake;&nbsp;<a href=\"https://medlineplus.gov/ency/article/002402.htm\" target=\"_blank\">vitamin B6</a> (pyridoxine); calcium-oxalate crystallization inhibitors (citrate, pyrophosphate, and magnesium); kidney stone therapies; and dialysis in some cases. Liver and/or kidney transplantation may be needed.[12025]","dateModified":"2016-08-12T00:00:00"},"basicQuestions":[{"questionId":10960,"questionText":"What are the signs and symptoms of primary hyperoxaluria type 1?","answerText":"The symptoms and severity of primary hyperoxaluria type 1 (PH1) can vary. The age that symptoms begin ranges from birth to the sixth decade of life (although there are exceptions). About 19% of people with PH1 have a severe, very early-onset form that becomes apparent within a few months after birth. At the milder end of the spectrum, some people with PH1 go without any symptoms for over 40 or 50 years. The <a href=\"In primary hyperoxaluria type 1 (PH1), supersaturation of the urine with oxalate leads to nephrolithiasis/nephrocalcinosis, renal tubular damage, and renal failure with eventual development of systemic manifestations (oxalosis) [Marangella et al 2001]. The presentation of PH1 is variable. Age at onset of symptoms ranges from birth to the sixth decade (median age: 5-6 years) [Lieske et al 2005b]; exceptions occur.  Approximately 19% of affected individuals present with a severe, very early-onset form of PH1 in the first few months of life. At the other end of the spectrum of clinical severity seen in PH1, some individuals remain apparently asymptomatic for more than 40-50 years\" target=\"_blank\">median</a> age of onset is about 5-6 years.<br />\r\n<br />\r\nFeatures of renal involvement can range from <a href=\"https://medlineplus.gov/ency/article/000492.htm\" target=\"_blank\">nephrocalcinosis</a>&nbsp;and renal failure in infancy, to only occasional stones diagnosed in adulthood.[12024]&nbsp;Kidney stones are commonly the first sign of hyperoxaluria. Symptoms of kidney stones can include&nbsp;sudden abdominal or flank pain; blood in the urine; frequent urge to urinate; pain while urinating; or fever and chills.[12030]<br />\r\n<br />\r\nUntreated PH1 leads to kidney failure, which is life-threatening. Symptoms of kidney failure can include decreased or no urine output; feeling ill or tired; loss of appetite; nausea and vomiting; and pale skin due to anemia.[12030]","dateModified":"2016-08-12T10:59:00","resourceClassificationName":"Symptoms","references":[{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12030,"authors":"","articleTitle":"Symptoms","bookWebsiteJournalTitle":"Oxalosis & Hyperoxaluria Foundation","date":"2015","volume":"","pages":"","url":"http://ohf.org/symptoms/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10961,"questionText":"What causes primary hyperoxaluria type 1?","answerText":"Primary hyperoxaluria type 1 is caused by <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>&nbsp;in a gene called&nbsp;<em><a href=\"https://ghr.nlm.nih.gov/gene/AGXT\" target=\"_blank\">AGXT</a></em>. This gene gives the body instructions for making  an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002353.htm\" target=\"_blank\">enzyme</a> called alanine-glyoxylate aminotransferase. This enzyme is found in cell structures called peroxisomes in liver cells. It converts a compound called glyoxylate to the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002222.htm\" target=\"_blank\">amino acid</a> glycine.<br />\r\n<br />\r\nMutations in the <em>AGXT </em>gene&nbsp;lead to a decrease in the amount or function of the enzyme, preventing  the breakdown of glyoxylate. This is turn causes glyoxylate to accumulate, and it is converted to oxalate instead of glycine. Excess oxalate that is not excreted from the body then combines with calcium to form calcium oxalate, which damages the kidneys and other organs.[12023]","dateModified":"2016-08-15T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":12023,"authors":"","articleTitle":"Primary hyperoxaluria","bookWebsiteJournalTitle":"Genetics Home Reference","date":"December, 2015","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/primary-hyperoxaluria","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10962,"questionText":"How is primary hyperoxaluria type 1 inherited?","answerText":"Primary hyperoxaluria type 1 is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[12024] This means that to be affected, a person must have a <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a> in both copies of the responsible <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in each cell. Affected people inherit one mutated copy of the gene from each parent, who is referred to as a&nbsp;<a href=\"http://www.genome.gov/glossary/?id=23\" target=\"_blank\">carrier</a>. Carriers of an autosomal recessive condition typically do not have any signs or symptoms (they are unaffected). When 2 carriers of an autosomal recessive condition have children, each child has a:\r\n<ul>\r\n    <li>25% chance to be affected</li>\r\n    <li>50% chance to be an unaffected carrier like each parent</li>\r\n    <li>25% chance to be unaffected&nbsp;<em>and</em>&nbsp;not  a carrier</li>\r\n</ul>","dateModified":"2016-08-15T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10963,"questionText":"How might primary hyperoxaluria type 1 be treated?","answerText":"The goal of treatment for primary hyperoxaluria type 1 (PH1) is to minimize calcium oxalate deposition and maintain renal function. Early diagnosis and prompt therapy is critical to preserve the function of the kidneys for as long as possible.<br />\r\n<br />\r\nGeneral therapies for preventing kidney stones benefit all people with PH1. Recommendations for this include:<br />\r\n<ul>\r\n    <li>drinking large amounts of fluid</li>\r\n    <li><a href=\"http://www.mayoclinic.org/drugs-supplements/potassium-citrate-oral-route/description/drg-20074773\" target=\"_blank\">oral potassium citrate</a> to inhibit calcium oxalate crystallization</li>\r\n    <li>drugs such as thiazides to decrease calcium in the urine</li>\r\n    <li>avoiding significant intake of vitamin C or D (they promote stone formation)</li>\r\n    <li>supplementation of dietary calcium</li>\r\n</ul>\r\n<p>Treatment for kidney stones may involve <a href=\"https://www.kidney.org/atoz/content/kidneystones_shockwave\" target=\"_blank\">shock wave lithotripsy</a>,&nbsp;<a href=\"https://www.kidney.org/atoz/content/kidneystones_PNN\" target=\"_blank\">percutaneous nephrolithotomy</a>, and/or <a href=\"https://www.kidney.org/atoz/content/kidneystones_ureteroscopy\" target=\"_blank\">ureteroscopy</a>.<br />\r\n<br />\r\nReducing the body's production of oxalate involves treatment with&nbsp;<a href=\"https://medlineplus.gov/druginfo/meds/a682587.html\" target=\"_blank\">pyridoxine</a>. While only about 10%-30% of people with PH1 respond to treatment with pyridoxine, it has been recommended that all people with PH1 receive a minimum 3-month trial at the time of initial diagnosis.<br />\r\n<br />\r\nDialysis to remove oxalate in people with PH1 has limitations, but may be indicated in specific circumstances in some people with PH1.<br />\r\n<br />\r\nLastly, organ transplantation is an option for therapy. There has been much discussion among experts regarding the best transplantation strategy for people with PH1. Depending on each person's response to other therapies and the disease severity, options may include combined liver-kidney transplant; sequential liver-kidney transplant; an isolated kidney transplant, or an isolated liver transplant.[12024]</p>\r\nOther therapies for PH1 are under investigation and may become options for people with PH1 in the future.<br />\r\n<br />\r\nPeople with questions about the treatment of PH1 for themselves or family members should speak with their doctor for treatment options and advice.","dateModified":"2016-08-15T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10964,"questionText":"What is the long-term outlook for people with primary hyperoxaluria type 1?","answerText":"The progression and severity of primary hyperoxaluria type 1 (PH1) varies. Specific <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> in the responsible gene (<em><a href=\"https://ghr.nlm.nih.gov/gene/AGXT\" target=\"_blank\">AGXT</a></em>) may correspond  with particular symptoms, disease progression, and response to treatment. For example, some people with PH1 respond to treatment with vitamin B6 (pyridoxine), while others do not. Some research suggests that specific mutations in the <em>AGXT</em> gene are associated with later onset end stage renal failure.[12051]<br />\r\n<br />\r\nThe outlook is very poor if  PH1 is left untreated.[12025] An early and accurate diagnosis leading to aggressive supportive treatment is a major factor in short- and long-term outcomes.[12052]&nbsp;In the future, the prognosis may be improved by new therapies.[12025]","dateModified":"2016-08-16T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12025,"authors":"Pierre Cochat","articleTitle":"Primary hyperoxaluria type 1","bookWebsiteJournalTitle":"Orphanet","date":"June, 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93598","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12051,"authors":"","articleTitle":"Primary Hyperoxaluria","bookWebsiteJournalTitle":"NORD","date":"2014","volume":"","pages":"","url":"http://rarediseases.org/rare-diseases/primary-hyperoxaluria","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12052,"authors":"Pierre Cochat et. al","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"Nephrology Dialysis Transplantation","date":"2012","volume":"27(5)","pages":"1729-1736","url":"http://www.medscape.com/viewarticle/764202_5","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":12476,"relatedDiseaseName":"Disorder of peroxisomal alpha-, beta- and omega-oxidation","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":12477,"relatedDiseaseName":"Disorders with deficiency of a single peroxisomal enzyme","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":8398,"relatedDiseaseName":"Peroxisome disorders","relation":"Parent","isRare":false,"hasGardPage":true}],"gardCases":[{"caseId":57811,"abbreviatedInquiry":"My 4 year old grandson was just diagnosed with primary hyperoxaluria 1. We need as much information as we can get.","caseQuestions":[{"questionId":9490,"questionText":"What is primary hyperoxaluria type 1?","answerText":"<strong>Primary hyperoxaluria type 1</strong> (PH1) is a rare disorder that mainly affects the kidneys. It results from buildup of a substance called oxalate, which normally is filtered through the kidneys and excreted in the urine. In people with PH1, the accumulated oxalate is deposited in the kidneys and urinary tract. It combines with calcium, forming the main component of kidney and bladder stones (calcium oxalate).[12023][12024]<br />\r\n<br />\r\nSigns and symptoms of PH1 vary in severity and may begin any time from infancy to early adulthood. Symptoms may include recurrent <a href=\"https://medlineplus.gov/ency/article/000458.htm\" target=\"_blank\">kidney stones</a>; blood in the urine; and urinary tract infections. Left untreated, PH1 can result in <a href=\"https://medlineplus.gov/kidneyfailure.html\" target=\"_blank\">end-stage renal disease</a>, which is life-threatening.[12023][12024]<br />\r\n<br />\r\nPH1 is due to <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>  in a gene called <em><a href=\"https://ghr.nlm.nih.gov/gene/AGXT\" target=\"_blank\">AGXT</a></em>. Inheritance is <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a>.[12023]<br />\r\n<br />\r\nEarly treatment is important for maintaining kidney function. Each person's treatment plan depends on his/her symptoms and the severity of the condition. Management may involve high fluid intake;&nbsp;<a href=\"https://medlineplus.gov/ency/article/002402.htm\" target=\"_blank\">vitamin B6</a> (pyridoxine); calcium-oxalate crystallization inhibitors (citrate, pyrophosphate, and magnesium); kidney stone therapies; and dialysis in some cases. Liver and/or kidney transplantation may be needed.[12025]","dateModified":"2016-08-12T00:00:00","references":[{"referenceId":9725,"authors":"Lorenz EC, Michet CJ, Milliner DS & Lieske JC","articleTitle":"Update on oxalate crystal disease","bookWebsiteJournalTitle":"Curr Rheumatol Rep. 2013 Jul;.","date":"July, 2013","volume":"15(7)","pages":"340","url":"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710657/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12023,"authors":"","articleTitle":"Primary hyperoxaluria","bookWebsiteJournalTitle":"Genetics Home Reference","date":"December, 2015","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/primary-hyperoxaluria","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12025,"authors":"Pierre Cochat","articleTitle":"Primary hyperoxaluria type 1","bookWebsiteJournalTitle":"Orphanet","date":"June, 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93598","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10960,"questionText":"What are the signs and symptoms of primary hyperoxaluria type 1?","answerText":"The symptoms and severity of primary hyperoxaluria type 1 (PH1) can vary. The age that symptoms begin ranges from birth to the sixth decade of life (although there are exceptions). About 19% of people with PH1 have a severe, very early-onset form that becomes apparent within a few months after birth. At the milder end of the spectrum, some people with PH1 go without any symptoms for over 40 or 50 years. The <a href=\"In primary hyperoxaluria type 1 (PH1), supersaturation of the urine with oxalate leads to nephrolithiasis/nephrocalcinosis, renal tubular damage, and renal failure with eventual development of systemic manifestations (oxalosis) [Marangella et al 2001]. The presentation of PH1 is variable. Age at onset of symptoms ranges from birth to the sixth decade (median age: 5-6 years) [Lieske et al 2005b]; exceptions occur.  Approximately 19% of affected individuals present with a severe, very early-onset form of PH1 in the first few months of life. At the other end of the spectrum of clinical severity seen in PH1, some individuals remain apparently asymptomatic for more than 40-50 years\" target=\"_blank\">median</a> age of onset is about 5-6 years.<br />\r\n<br />\r\nFeatures of renal involvement can range from <a href=\"https://medlineplus.gov/ency/article/000492.htm\" target=\"_blank\">nephrocalcinosis</a>&nbsp;and renal failure in infancy, to only occasional stones diagnosed in adulthood.[12024]&nbsp;Kidney stones are commonly the first sign of hyperoxaluria. Symptoms of kidney stones can include&nbsp;sudden abdominal or flank pain; blood in the urine; frequent urge to urinate; pain while urinating; or fever and chills.[12030]<br />\r\n<br />\r\nUntreated PH1 leads to kidney failure, which is life-threatening. Symptoms of kidney failure can include decreased or no urine output; feeling ill or tired; loss of appetite; nausea and vomiting; and pale skin due to anemia.[12030]","dateModified":"2016-08-12T10:59:00","resourceClassificationName":"Symptoms","references":[{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12030,"authors":"","articleTitle":"Symptoms","bookWebsiteJournalTitle":"Oxalosis & Hyperoxaluria Foundation","date":"2015","volume":"","pages":"","url":"http://ohf.org/symptoms/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10965,"questionText":"What is recommended following an initial diagnosis of primary hyperoxaluria type 1?","answerText":"When a person is diagnosed with primary hyperoxaluria type 1 (PH1), the extent of disease and treatment needs should be evaluated. Recommended evaluations for everyone include:<br />\r\n<ul>\r\n    <li><span style=\"font-size: 12pt;\">Molecular genetic testing of the <em>AGXT</em> gene</span></li>\r\n    <li><span style=\"font-size: 12pt;\">Clinical genetics consultation</span></li>\r\n</ul>\r\n<p>Further evaluation depends on the baseline renal function at the time of diagnosis and the evaluations performed as part of the diagnosis. The baseline renal function is measured with a&nbsp;<a href=\"https://www.kidney.org/atoz/content/gfr\" target=\"_blank\">glomerular filtration rate (GFR) test</a>. Depending on a person's GFR, additional tests <em>may</em> be recommended, such as:</p>\r\n<ul>\r\n    <li>renal ultrasound and&nbsp;<span style=\"font-size: 12pt;\"><a href=\"http://www.ncbi.nlm.nih.gov/books/NBK221/\" target=\"_blank\">fundoscopic eye examination</a> to check for oxalate deposition</span></li>\r\n    <li>baseline <a href=\"https://medlineplus.gov/urinalysis.html\" target=\"_blank\">urinalysis</a></li>\r\n    <li>measurement of <a href=\"http://www.mayomedicallaboratories.com/test-catalog/Overview/81408\" target=\"_blank\">plasma oxalate</a></li>\r\n    <li>bone x-rays or bone marrow examination</li>\r\n    <li>thyroid function testing</li>\r\n    <li><a href=\"http://www.heart.org/HEARTORG/Conditions/HeartAttack/SymptomsDiagnosisofHeartAttack/Electrocardiogram-ECG-or-EKG_UCM_309050_Article.jsp#.V7IAHPkrJhE\" target=\"_blank\">electrocardiogram</a> to check for an associated <a href=\"http://www.merckmanuals.com/home/heart-and-blood-vessel-disorders/abnormal-heart-rhythms/heart-block\" target=\"_blank\">atrioventricular block</a></li>\r\n    <li>ultrasound and/or CT scan of the heart and viscera</li>\r\n    <li><a href=\"https://medlineplus.gov/ency/article/003645.htm\" target=\"_blank\">hemoglobin</a> to evaluate for anemia associated with either renal dysfunction or marrow deposition of oxalate</li>\r\n    <li>history and physical exam to assess the risk of <a href=\"https://medlineplus.gov/ency/article/000725.htm\" target=\"_blank\">arterial insufficiency</a> or ischemia (obstruction of blood vessels)[12024]</li>\r\n</ul>","dateModified":"2016-08-15T00:00:00","references":[{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10961,"questionText":"What causes primary hyperoxaluria type 1?","answerText":"Primary hyperoxaluria type 1 is caused by <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a>&nbsp;in a gene called&nbsp;<em><a href=\"https://ghr.nlm.nih.gov/gene/AGXT\" target=\"_blank\">AGXT</a></em>. This gene gives the body instructions for making  an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002353.htm\" target=\"_blank\">enzyme</a> called alanine-glyoxylate aminotransferase. This enzyme is found in cell structures called peroxisomes in liver cells. It converts a compound called glyoxylate to the <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002222.htm\" target=\"_blank\">amino acid</a> glycine.<br />\r\n<br />\r\nMutations in the <em>AGXT </em>gene&nbsp;lead to a decrease in the amount or function of the enzyme, preventing  the breakdown of glyoxylate. This is turn causes glyoxylate to accumulate, and it is converted to oxalate instead of glycine. Excess oxalate that is not excreted from the body then combines with calcium to form calcium oxalate, which damages the kidneys and other organs.[12023]","dateModified":"2016-08-15T00:00:00","resourceClassificationName":"Cause","references":[{"referenceId":12023,"authors":"","articleTitle":"Primary hyperoxaluria","bookWebsiteJournalTitle":"Genetics Home Reference","date":"December, 2015","volume":"","pages":"","url":"https://ghr.nlm.nih.gov/condition/primary-hyperoxaluria","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10962,"questionText":"How is primary hyperoxaluria type 1 inherited?","answerText":"Primary hyperoxaluria type 1 is inherited in an <a href=\"http://www.nlm.nih.gov/medlineplus/ency/article/002052.htm\" target=\"_blank\">autosomal recessive</a> manner.[12024] This means that to be affected, a person must have a <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutation</a> in both copies of the responsible <a href=\"http://www.genome.gov/glossary/index.cfm?id=70\" target=\"_blank\">gene</a> in each cell. Affected people inherit one mutated copy of the gene from each parent, who is referred to as a&nbsp;<a href=\"http://www.genome.gov/glossary/?id=23\" target=\"_blank\">carrier</a>. Carriers of an autosomal recessive condition typically do not have any signs or symptoms (they are unaffected). When 2 carriers of an autosomal recessive condition have children, each child has a:\r\n<ul>\r\n    <li>25% chance to be affected</li>\r\n    <li>50% chance to be an unaffected carrier like each parent</li>\r\n    <li>25% chance to be unaffected&nbsp;<em>and</em>&nbsp;not  a carrier</li>\r\n</ul>","dateModified":"2016-08-15T00:00:00","resourceClassificationName":"Inheritance","references":[{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10963,"questionText":"How might primary hyperoxaluria type 1 be treated?","answerText":"The goal of treatment for primary hyperoxaluria type 1 (PH1) is to minimize calcium oxalate deposition and maintain renal function. Early diagnosis and prompt therapy is critical to preserve the function of the kidneys for as long as possible.<br />\r\n<br />\r\nGeneral therapies for preventing kidney stones benefit all people with PH1. Recommendations for this include:<br />\r\n<ul>\r\n    <li>drinking large amounts of fluid</li>\r\n    <li><a href=\"http://www.mayoclinic.org/drugs-supplements/potassium-citrate-oral-route/description/drg-20074773\" target=\"_blank\">oral potassium citrate</a> to inhibit calcium oxalate crystallization</li>\r\n    <li>drugs such as thiazides to decrease calcium in the urine</li>\r\n    <li>avoiding significant intake of vitamin C or D (they promote stone formation)</li>\r\n    <li>supplementation of dietary calcium</li>\r\n</ul>\r\n<p>Treatment for kidney stones may involve <a href=\"https://www.kidney.org/atoz/content/kidneystones_shockwave\" target=\"_blank\">shock wave lithotripsy</a>,&nbsp;<a href=\"https://www.kidney.org/atoz/content/kidneystones_PNN\" target=\"_blank\">percutaneous nephrolithotomy</a>, and/or <a href=\"https://www.kidney.org/atoz/content/kidneystones_ureteroscopy\" target=\"_blank\">ureteroscopy</a>.<br />\r\n<br />\r\nReducing the body's production of oxalate involves treatment with&nbsp;<a href=\"https://medlineplus.gov/druginfo/meds/a682587.html\" target=\"_blank\">pyridoxine</a>. While only about 10%-30% of people with PH1 respond to treatment with pyridoxine, it has been recommended that all people with PH1 receive a minimum 3-month trial at the time of initial diagnosis.<br />\r\n<br />\r\nDialysis to remove oxalate in people with PH1 has limitations, but may be indicated in specific circumstances in some people with PH1.<br />\r\n<br />\r\nLastly, organ transplantation is an option for therapy. There has been much discussion among experts regarding the best transplantation strategy for people with PH1. Depending on each person's response to other therapies and the disease severity, options may include combined liver-kidney transplant; sequential liver-kidney transplant; an isolated kidney transplant, or an isolated liver transplant.[12024]</p>\r\nOther therapies for PH1 are under investigation and may become options for people with PH1 in the future.<br />\r\n<br />\r\nPeople with questions about the treatment of PH1 for themselves or family members should speak with their doctor for treatment options and advice.","dateModified":"2016-08-15T00:00:00","resourceClassificationName":"Treatment","references":[{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10964,"questionText":"What is the long-term outlook for people with primary hyperoxaluria type 1?","answerText":"The progression and severity of primary hyperoxaluria type 1 (PH1) varies. Specific <a href=\"http://www.genome.gov/Glossary/index.cfm?id=134\" target=\"_blank\">mutations</a> in the responsible gene (<em><a href=\"https://ghr.nlm.nih.gov/gene/AGXT\" target=\"_blank\">AGXT</a></em>) may correspond  with particular symptoms, disease progression, and response to treatment. For example, some people with PH1 respond to treatment with vitamin B6 (pyridoxine), while others do not. Some research suggests that specific mutations in the <em>AGXT</em> gene are associated with later onset end stage renal failure.[12051]<br />\r\n<br />\r\nThe outlook is very poor if  PH1 is left untreated.[12025] An early and accurate diagnosis leading to aggressive supportive treatment is a major factor in short- and long-term outcomes.[12052]&nbsp;In the future, the prognosis may be improved by new therapies.[12025]","dateModified":"2016-08-16T00:00:00","resourceClassificationName":"Prognosis","references":[{"referenceId":12024,"authors":"Marion B Coulter-Mackie, Colin T White, Dirk Lange, and Ben H Chew","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"GeneReviews","date":"July 17, 2014","volume":"","pages":"","url":"http://www.ncbi.nlm.nih.gov/books/NBK1283/","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12025,"authors":"Pierre Cochat","articleTitle":"Primary hyperoxaluria type 1","bookWebsiteJournalTitle":"Orphanet","date":"June, 2013","volume":"","pages":"","url":"http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=93598","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12051,"authors":"","articleTitle":"Primary Hyperoxaluria","bookWebsiteJournalTitle":"NORD","date":"2014","volume":"","pages":"","url":"http://rarediseases.org/rare-diseases/primary-hyperoxaluria","authors2":"","placeOfPublication":"","publisher":""},{"referenceId":12052,"authors":"Pierre Cochat et. al","articleTitle":"Primary Hyperoxaluria Type 1","bookWebsiteJournalTitle":"Nephrology Dialysis Transplantation","date":"2012","volume":"27(5)","pages":"1729-1736","url":"http://www.medscape.com/viewarticle/764202_5","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[{"phenoTypeId":8160,"phenoTypeName":"Abnormality of circulating enzyme level","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":15539,"phenoTypeName":"Anemia","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":7346,"phenoTypeName":"Calcinosis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14470,"phenoTypeName":"Hyperoxaluria","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":13040,"phenoTypeName":"Metabolic acidosis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":10052,"phenoTypeName":"Nephrocalcinosis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":14159,"phenoTypeName":"Nephrolithiasis","frequencyText":"Very frequent","percentRanges":"80%-99%"},{"phenoTypeId":6262,"phenoTypeName":"Decreased glomerular filtration rate","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":11698,"phenoTypeName":"Dysuria","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":4081,"phenoTypeName":"Failure to thrive","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":14161,"phenoTypeName":"Hematuria","frequencyText":"Frequent","percentRanges":"30%-79%"},{"phenoTypeId":10252,"phenoTypeName":"Abnormality of the skeletal system","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":14173,"phenoTypeName":"Enuresis","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":6542,"phenoTypeName":"Recurrent urinary tract infections","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":7355,"phenoTypeName":"Stage 5 chronic kidney disease","frequencyText":"Occasional","percentRanges":"5%-29%"},{"phenoTypeId":9769,"phenoTypeName":"Abnormality of the dentition","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":13787,"phenoTypeName":"Atherosclerosis","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":9386,"phenoTypeName":"Stroke","frequencyText":"Very rare","percentRanges":"1%-4%"},{"phenoTypeId":9329,"phenoTypeName":"Acrocyanosis","percentRanges":"-"},{"phenoTypeId":11296,"phenoTypeName":"Arterial occlusion","percentRanges":"-"},{"phenoTypeId":9004,"phenoTypeName":"Atrioventricular block","percentRanges":"-"},{"phenoTypeId":4,"phenoTypeName":"Autosomal recessive inheritance","percentRanges":"-"},{"phenoTypeId":13280,"phenoTypeName":"Bone pain","percentRanges":"-"},{"phenoTypeId":1297,"phenoTypeName":"Calcinosis cutis","percentRanges":"-"},{"phenoTypeId":6209,"phenoTypeName":"Calcium oxalate nephrolithiasis","percentRanges":"-"},{"phenoTypeId":2861,"phenoTypeName":"Choroidal neovascularization","percentRanges":"-"},{"phenoTypeId":10292,"phenoTypeName":"Cutis marmorata","percentRanges":"-"},{"phenoTypeId":1833,"phenoTypeName":"Gangrene","percentRanges":"-"},{"phenoTypeId":14075,"phenoTypeName":"Increased bone mineral density","percentRanges":"-"},{"phenoTypeId":9204,"phenoTypeName":"Intermittent claudication","percentRanges":"-"},{"phenoTypeId":10124,"phenoTypeName":"Optic atrophy","percentRanges":"-"},{"phenoTypeId":3045,"phenoTypeName":"Optic neuropathy","percentRanges":"-"},{"phenoTypeId":10709,"phenoTypeName":"Pathologic fracture","percentRanges":"-"},{"phenoTypeId":9081,"phenoTypeName":"Peripheral arterial stenosis","percentRanges":"-"},{"phenoTypeId":2230,"phenoTypeName":"Peripheral neuropathy","percentRanges":"-"},{"phenoTypeId":14615,"phenoTypeName":"Raynaud phenomenon","percentRanges":"-"},{"phenoTypeId":10015,"phenoTypeName":"Renal insufficiency","percentRanges":"-"},{"phenoTypeId":1319,"phenoTypeName":"Retinal crystals","percentRanges":"-"},{"phenoTypeId":10492,"phenoTypeName":"Retinopathy","percentRanges":"-"}],"medicalProducts":[],"EncodedName":"Primary_hyperoxaluria_type_1"}